SequelSEC

ATOSSA THERAPEUTICS, INC. ATOS

Pharmaceutical Preparations · CIK 0001488039 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2016-09-30
Operating income
-$1.56M
Fiscal year ended 2016-09-30
Free cash flow
Unavailable
Fiscal year ended 2016-09-30

ATOSSA THERAPEUTICS, INC. (ATOS) reported revenue of $0 and net income of $204.69K for the fiscal year ended 2016-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ATOSSA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ATOSSA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Revenue$0$0$0$1.76K$0$0$0$2.71K$3.43K$9.88K
Cost of revenueUnavailable$0$0-$3.24M$313.41K$0$0$0$0$0
Gross profitUnavailable$0$0-$2.09M$458.84K$0$0$2.71K$3.43K$9.88K
Operating income-$1.56M-$1.72M-$2.33M-$2.47M-$3.84M-$3.17M-$3.27M-$3.33M-$3.25M-$3.19M
Net income$204.69K-$1.72M-$2.33M-$4.96M-$4.32M-$3.15M-$3.34M-$5.81M-$3.25M-$3.19M
Research & development$85.00K$168.99K$149.97K$471.36K$948.96K$373.47K$565.80K-$746.11K$923.17K$510.77K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income$204.69K-$1.72M-$2.33M-$2.59M-$3.77M-$3.12M-$3.27M-$3.33M-$3.25M-$3.19M
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.47M$1.55M$2.18M$1.64M$2.40M$2.45M$2.36M$1.77M$2.04M$2.46M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ATOSSA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Cash & equivalents$4.39M$1.19M$2.88M$3.72M$7.84M$11.40M$9.73M$8.50M$11.37M$14.30M
Total assets$6.28M$3.28M$5.10M$6.24M$12.36M$16.56M$13.80M$11.76M$16.77M$19.82M
Current assets$4.56M$1.45M$3.39M$4.29M$9.54M$13.76M$11.37M$9.34M$11.72M$14.67M
Total liabilitiesUnavailableUnavailableUnavailable$2.50M$3.30M$3.44M$3.52M$2.27MUnavailableUnavailable
Current liabilities$863.77K$874.26K$1.33M$2.50M$3.29M$3.41M$3.49M$2.26M$1.54M$1.56M
Total equity incl. NCI$5.41M$2.41M$3.77M$3.74M$9.06M$13.12M$10.28M$9.50M$15.23M$18.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable$0$170.86K$101.34K$94.63K$9.28K$45.87K$1.91K
Accounts receivableUnavailableUnavailableUnavailableUnavailable$1.06M$2.01M$1.28M$297.96K$29.15K$48.16K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$0$12.53K$25.23K$49.22KUnavailableUnavailable
Accounts payable$197.35K$282.79K$429.05K$814.45K$1.18M$580.54K$966.21K$513.04K$439.25K$790.18K

Cash flow

ATOSSA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Operating cash flow$635.50K-$1.66M-$2.99M-$3.95M-$3.48M-$3.52M-$3.00MUnavailableUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$82$79-$5.02K-$177.67K-$29.08K-$15.63K-$66.04KUnavailableUnavailableUnavailable
Financing cash flow$2.56MUnavailableUnavailableUnavailable-$53.86KUnavailableUnavailableUnavailableUnavailableUnavailable
Net change in cash$3.20M-$1.69M-$833.24K-$4.12M-$3.56M$1.67M$1.23M-$2.87M-$2.92M-$2.29M
Stock-based compensation$257.39K$200.19K$192.46K$206.14K$317.99K$205.11K$148.87K$11.17K$147.40K$167.53K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$74.81K$76.84K$75.73K$104.36K$112.97K-$8.95K$64.25K$99.34K$128.05K$127.83K

Derived

ATOSSA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable-119126.9%UnavailableUnavailableUnavailable100.0%100.0%100.0%
Operating marginUnavailableUnavailableUnavailable-140733.6%UnavailableUnavailableUnavailable-122680.2%-94724.3%-32268.7%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable411.8%UnavailableUnavailable
Current ratio5.28x1.66x2.55x1.72x2.90x4.03x3.26x4.13x7.61x9.39x
Revenue YoY growthUnavailableUnavailableUnavailable-35.2%-100.0%-100.0%-100.0%UnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable-282229.6%UnavailableUnavailableUnavailable-214265.5%-94728.4%-32283.3%
R&D / revenueUnavailableUnavailableUnavailable26812.1%UnavailableUnavailableUnavailable-27501.3%26946.0%5172.3%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable0.00x0.00x0.00xUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.